Publications by authors named "M Asuncion Iborra-Bendicho"
Cerebral echinococcosis: Case report and literature review.
Enferm Infecc Microbiol Clin (Engl Ed)
February 2023
Echinococcosis is a zoonosis caused by the larval form of the cestode Echinococcus granulosus. The cerebral affectation in the human is uncommon; only in 1-2% cases is observed encephalic involvement. This condition occurs mainly in the pediatric population and it is characterized by the presence of single and unilocular cysts.
View Article and Find Full Text PDFCerebral echinococcosis: Case report and literature review.
Enferm Infecc Microbiol Clin (Engl Ed)
August 2021
Article Synopsis
- Echinococcosis is a disease caused by the Echinococcus granulosus parasite, and brain involvement is rare, occurring in only 1-2% of cases, mostly in children, characterized by single cysts.
- A case study of a 29-year-old patient with severe headaches revealed a mass in the brain, which was identified as a bilobed hydatid cyst.
- The report will discuss the clinical, epidemiological, diagnostic, and treatment aspects related to cerebral hydatid disease.
Erratum to "Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: Safety algorithm" [Neurologia. 2020;35(6):357-362].
Neurologia (Engl Ed)
September 2020
Introduction: The COVID-19 pandemic is changing approaches to diagnosis, treatment, and care provision in multiple sclerosis (MS). During both the initial and peak phases of the epidemic, the administration of disease-modifying drugs, typically immunosuppressants administered in pulses, was suspended due to the uncertainty about their impact on SARS-CoV-2 infection, mainly in contagious asymptomatic/presymptomatic patients. The purpose of this study is to present a safety algorithm enabling patients to resume pulse immunosuppressive therapy (PIT) during the easing of lockdown measures.
View Article and Find Full Text PDF[ARCHITECT Chagas(®): a new diagnostic tool in Chagas disease].
Enferm Infecc Microbiol Clin
October 2012
Objective: To evaluate a new chemiluminescent microparticle immunoassay (ARCHITECT Chagas(®), Abbott).
Methods: In this study, 165 samples were tested by two different serological tests. The ARCHITECT Chagas(®) assay was performed using ARCHITECT i2000(SR) system (Abbott).